Covered Companies: enVVeno Medical
Most Recent Event
Closing Bell
June 9, 2026 4:00 PM ET
Rob Berman, CEO discussed the Company’s recently reported IDE approval of its enVVe® System, marking a first-ever FDA
IDE approval for a U.S. pivotal study of a
non-surgical replacement venous valve.

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.
NASDAQ: NVNO
About
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company is currently developing the enVVe system, which includes a first-in-class non-surgical replacement venous valve being developed for the treatment of severe Deep Venous Insufficiency (DVI). The enVVe valve is designed to act as one-way valve, to help assist in propelling blood up the leg, and back to the heart and lungs. As a transcatheter delivered device, the enVVe procedure will be performed under light sedation and should not require an over-night hospital stay.
Past Events
“What This Means”
May 12, 2026
Rob Berman, CEO discusses the Company’s recent news announcing the U.S. Food and Drug Administration’s (FDA) first-ever IDE approval awarded to enVVeno to proceed with a U.S. pivotal study of a non-surgical replacement venous valve.

“CEO Connect”
Wednesday, December 3, 2025
